Phenotypic heterogeneity in IGHV-mutated CLL patients has prognostic impact and identifies a subset with increased sensitivity to BTK and PI3Kδ inhibition

por Pepper, C, Buggins, A G S, Jones, C H, Walsby, E J, Forconi, F, Pratt, G, Devereux, S, Stevenson, F K, Fegan, C
Publicado 2015

PI3Kδ inhibition elicits anti-leukemic effects through Bim-dependent apoptosis

por Carter, M J, Cox, K L, Blakemore, S J, Turaj, A H, Oldham, R J, Dahal, L N, Tannheimer, S, Forconi, F, Packham, G, Cragg, M S
Publicado 2017

P1130: ACALABRUTINIB IN TREATMENT-NAIVE OR RELAPSED/REFRACTORY WALDENSTRÖM MACROGLOBULINEMIA: 5-YEAR FOLLOW-UP OF A PHASE 2, SINGLE-ARM STUDY

por Owen, R., McCarthy, H., Rule, S., D’Sa, S., Thomas, S., Tournilhac, O., Forconi, F., José Kersten, M., Luigi Zinzani, P., Iyengar, S., Kothari, J., Minnema, M., Kastritis, E., Cheson, B., Walter, H., Greewald, D., Calvo, R., Wun, C.-C., Furman, R.
Publicado 2022

Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia

por Parker, H, Rose-Zerilli, M J J, Larrayoz, M, Clifford, R, Edelmann, J, Blakemore, S, Gibson, J, Wang, J, Ljungström, V, Wojdacz, T K, Chaplin, T, Roghanian, A, Davis, Z, Parker, A, Tausch, E, Ntoufa, S, Ramos, S, Robbe, P, Alsolami, R, Steele, A J, Packham, G, Rodríguez-Vicente, A E, Brown, L, McNicholl, F, Forconi, F, Pettitt, A, Hillmen, P, Dyer, M, Cragg, M S, Chelala, C, Oakes, C C, Rosenquist, R, Stamatopoulos, K, Stilgenbauer, S, Knight, S, Schuh, A, Oscier, D G, Strefford, J C
Publicado 2016